Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$0.09
-25.0%
$0.18
$0.09
$1.00
$2.68M0.251.84 million shs2.33 million shs
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$5.89
-4.1%
$5.93
$5.26
$11.38
$235.92M0.67557,200 shs437,388 shs
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$6.90
-9.2%
$8.42
$3.78
$13.62
$381.02M1.73179,391 shs147,815 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$31.59
-0.9%
$28.59
$16.79
$39.41
$450.47M1.0463,193 shs32,312 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
+14.95%-18.00%-26.17%-34.82%-86.89%
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-0.97%+6.04%-12.66%+0.99%-31.47%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-1.68%+3.12%+0.40%-11.63%-5.24%
Surmodics, Inc. stock logo
SRDX
Surmodics
-1.88%+24.06%+17.69%+3.47%+53.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.5242 of 5 stars
3.52.00.04.23.13.31.3
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
0.4245 of 5 stars
0.00.00.04.21.73.30.0
Surmodics, Inc. stock logo
SRDX
Surmodics
4.331 of 5 stars
3.52.00.03.43.01.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/A
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25141.94% Upside
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$57.0080.44% Upside

Current Analyst Ratings

Latest AFIB, PLSE, ANGO, ATRS, and SRDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$71.00 ➝ $71.00
5/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $43.00
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$7.16M0.37N/AN/A($0.03) per share-3.00
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$324.01M0.73$1.03 per share5.72$9.64 per share0.61
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K544.31N/AN/A$0.81 per share8.52
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M3.40$0.76 per share41.43$8.48 per share3.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
-$81.66M-$1.24N/AN/A-166.79%-35.31%-13.43%5/9/2024 (Estimated)
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%8/8/2024 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.9533.25N/AN/A9.44%13.30%8.63%8/7/2024 (Estimated)

Latest AFIB, PLSE, ANGO, ATRS, and SRDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q2 2024
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.36$0.07+$0.43$0.12$28.79 million$31.96 million    
4/4/2024Q3 2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$0.14-$0.16-$0.02$4.41N/AN/A
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/A
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
1.10
2.44
2.22
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.39
3.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
56.91%
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
3.50%
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
71.50%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
23029.72 million28.68 millionOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million15.74 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.26 million12.99 millionOptionable

AFIB, PLSE, ANGO, ATRS, and SRDX Headlines

SourceHeadline
Surmodics (NASDAQ:SRDX) Receives Outperform Rating from Barrington ResearchSurmodics (NASDAQ:SRDX) Receives Outperform Rating from Barrington Research
americanbankingnews.com - May 6 at 5:38 AM
Q3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by AnalystQ3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Analyst
americanbankingnews.com - May 6 at 3:50 AM
Surmodics, Inc. Just Beat Earnings Expectations: Heres What Analysts Think Will Happen NextSurmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
finance.yahoo.com - May 4 at 11:04 AM
Surmodics (SRDX) Q2 Earnings Top Estimates, 24 View UpSurmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
zacks.com - May 3 at 2:16 PM
Surmodics (NASDAQ:SRDX) Price Target Cut to $43.00Surmodics (NASDAQ:SRDX) Price Target Cut to $43.00
americanbankingnews.com - May 3 at 5:18 AM
Surmodics (NASDAQ:SRDX) Rating Reiterated by Barrington ResearchSurmodics (NASDAQ:SRDX) Rating Reiterated by Barrington Research
marketbeat.com - May 2 at 3:39 PM
Surmodics (NASDAQ:SRDX) Releases  Earnings Results, Beats Expectations By $0.43 EPSSurmodics (NASDAQ:SRDX) Releases Earnings Results, Beats Expectations By $0.43 EPS
marketbeat.com - May 2 at 2:16 PM
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
markets.businessinsider.com - May 2 at 12:58 PM
Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
finance.yahoo.com - May 2 at 7:36 AM
Surmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo FinanceSurmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - May 1 at 9:25 PM
SurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating ReaffirmedSurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating Reaffirmed
markets.businessinsider.com - May 1 at 9:25 PM
Surmodics (NASDAQ:SRDX) PT Lowered to $43.00Surmodics (NASDAQ:SRDX) PT Lowered to $43.00
marketbeat.com - May 1 at 3:06 PM
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024
investorplace.com - May 1 at 1:02 PM
Surmodics (NASDAQ:SRDX) Issues FY 2024 Earnings GuidanceSurmodics (NASDAQ:SRDX) Issues FY 2024 Earnings Guidance
marketbeat.com - May 1 at 10:57 AM
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesSurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com - May 1 at 10:35 AM
SurModics (SRDX) Q2 Earnings and Revenues Top EstimatesSurModics (SRDX) Q2 Earnings and Revenues Top Estimates
zacks.com - May 1 at 9:31 AM
SurModics: Fiscal Q2 Earnings SnapshotSurModics: Fiscal Q2 Earnings Snapshot
timesunion.com - May 1 at 9:28 AM
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceSurmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
businesswire.com - May 1 at 7:00 AM
SurModics earnings: heres what Wall Street expectsSurModics earnings: here's what Wall Street expects
markets.businessinsider.com - April 30 at 1:24 PM
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
finance.yahoo.com - April 30 at 1:24 PM
Surmodics (SRDX) Set to Announce Quarterly Earnings on WednesdaySurmodics (SRDX) Set to Announce Quarterly Earnings on Wednesday
marketbeat.com - April 24 at 6:45 AM
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
businesswire.com - April 19 at 7:00 AM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acutus Medical logo

Acutus Medical

NASDAQ:AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.
AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Antares Pharma logo

Antares Pharma

NASDAQ:ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.